Prof Salomon's Research Featured on Journal Cover
(Left) Prof Christine Salomon's research has been featured on the cover of the journal Developmental Dynamics. The image shows a zebrafish with an amputated tail that was then treated with their fungal compound colomitide. This compound was isolated by the Salomon goup from a fungus collected from a historic hut in Antarctica.
(Right) Professor Salomon and her colleagues' research on antifungal discovery to treat white nose syndrome (WNS) in bats has been featured on the Minnesota Daily (picture courtesy Emily Urfer). Read the full story by Becca Most: Click Here
Minnesota Researchers Look Alzheimer's in the Eye: BTN LiveBIG
If there was a way to catch Alzheimer's earlier, to see its onset in the most nascent of stages, medical researchers postulate that would allow patients to access novel treatments earlier than ever before. At the University of Minnesota's Center for Drug Design (CDD), researchers are working towards that goal. First, however, the must surmount the problem of early detection. Read the article by John Tolley (and watch the video): Here
Photo by Brady Willette
Finding a viable treatment for Alzheimer’s disease (AD) continues to frustrate researchers around the world. The University of Minnesota Center for Drug Design’s Robert Vince, PhD, and Swati More, PhD, aren’t exempt.
Vince, More, and their colleagues are developing a drug to treat early AD, but they wanted a faster way to test whether their compound was working. So they created a cost-effective, noninvasive eye-scanning technology to do the job, and their breakthrough is commanding international attention. Read the full story by Barbara Knox: Click Here
Prof Steve Patterson Receives NIH Grant To Develop Cyanide Antidote Autoinjector
The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning. Read More
Message from the Director
The Center for Drug Design (CDD) was created to combine research and scholarship leading to the development of novel drugs for therapeutic applications, such as HIV, cancer, neurological diseases, dermatological agents, infectious diseases, novel processes, and medical devices. The Center for Drug Design combines the best of academic tradition along with an expectation of innovation and independence, and provides significant value for our academic and research community.
Please contact the host (Zhengqiang Wang, PhD) for the link to attend this virtual seminar.
Title: Inhibitors of HIV-1 Attachment: The Discovery of Temsavir and its Prodrug Fostemsavir
This presentation will summarize the structure−activity and structure−liability studies leading to the discovery of temsavir and the clinical studies that entailed the development of an extended-release formulation suitable for further development. Fostemsavir was approved for clinical use by the FDA in July 2020 and by the EMA in February 2021 and is marketed as Rukobia.